BioCryst Pharmaceuticals (NASDAQ: BCRX – Get a rating) and Allena Pharmaceuticals (NASDAQ: ALNA – Get a rating) are both small-cap medical companies, but which is the better investment? We’ll compare the two companies based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk, and analyst recommendations.
This table compares the net margins, return on equity and return on assets of BioCryst Pharmaceuticals and Allena Pharmaceuticals.
|Net margins||Return on equity||return on assets|
|BioCryst Pharmaceuticals||-103.16%||N / A||-66.25%|
|Allena Pharmaceuticals||N / A||-241.30%||-130.30%|
This is a summary of current recommendations and price targets for BioCryst Pharmaceuticals and Allena Pharmaceuticals, as reported by MarketBeat.com.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
BioCryst Pharmaceuticals currently has a consensus target price of $18.64, suggesting a potential upside of 105.02%. Allena Pharmaceuticals has a consensus target price of $3.00, suggesting a potential upside of 2,639.73%. Given Allena Pharmaceuticals’ likely higher upside, analysts clearly believe that Allena Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.
Volatility and risk
BioCryst Pharmaceuticals has a beta of 2.51, suggesting its stock price is 151% more volatile than the S&P 500. In comparison, Allena Pharmaceuticals has a beta of 1.97, suggesting its stock price is 97% more volatile than the S&P 500.
Institutional and insider ownership
63.9% of BioCryst Pharmaceuticals shares are held by institutional investors. By comparison, 22.5% of Allena Pharmaceuticals’ shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by insiders. By comparison, 10.1% of Allena Pharmaceuticals’ shares are held by insiders. Strong institutional ownership indicates that hedge funds, large money managers, and endowments believe a company is poised for long-term growth.
Valuation and benefits
This table compares the revenue, earnings per share (EPS), and valuation of BioCryst Pharmaceuticals and Allena Pharmaceuticals.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|BioCryst Pharmaceuticals||$157.17 million||10.73||-$184.06 million||($1.07)||-8.50|
|Allena Pharmaceuticals||N / A||N / A||-$48.66 million||($0.86)||-0.13|
Allena Pharmaceuticals has lower revenues, but higher profits than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals trades at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals beats Allena Pharmaceuticals on 7 out of 12 factors compared between the two stocks.
BioCryst Pharmaceuticals Company Profile (Get a rating)
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel oral and small molecule drugs. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the names RAPIVAB, RAPIACTA and PERAMIFLU; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in a phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in a Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, yellow fever, Ebola and Zika. The Company has collaborations and licensing relationships with Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd. ; Green Cross Society; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Advanced Biomedical Research and Development Authority; the US Department of Health and Human Services; and the University of Alabama at Birmingham, as well as Albert Einstein College of Medicine at Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Allena Pharmaceuticals Company Profile (Get a rating)
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops and markets oral enzyme therapies to treat patients with rare and serious metabolic and renal disorders in the United States. Its lead product candidate is ALLN-346, a novel urate-degrading enzyme for patients with hyperuricemia and gout in advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Get news and reviews for BioCryst Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com’s FREE daily newsletter.